Copyright
©The Author(s) 2016.
World J Gastrointest Pharmacol Ther. Nov 6, 2016; 7(4): 477-489
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.477
Published online Nov 6, 2016. doi: 10.4292/wjgpt.v7.i4.477
Table 4 Randomized controlled trials comparing transarterial chemoembolization combined to radiofrequency ablation vs radiofrequency ablation alone in hepatocellular carcinoma patients
| Ref. | Region | Patients (n) | Tumor size, cm | CP A/B/C | 3-yr survival (%) | 3-yr recurrence (%) |
| Peng et al[75] | China | TACE + RFA (69) | ≤ 5.01 | 60/9/0 | 69.0 | 45.0 |
| RFA (70) | - | 59/11/0 | 47.0 | 18.0 | ||
| Cheng et al[76] | China | TACE + RFA (96) | ≤ 7.5 | NA | 55.0 | NA |
| RFA (100) | - | NA | 32.0 | NA | ||
| Yang et al[77] | China | TACE + RFA (24) | 6.6 ± 0.6 | NA | NA | NA |
| RFA (12) | 5.2 ± 0.4 | NA | NA | NA | ||
| Shibata et al[78] | Japan | TACE + RFA (46) | 1.7 ± 0.6 | 32/14/0 | 84.8 | 48.8 |
| RFA (43) | 1.6 ± 0.5 | 33/10/0 | 84.5 | 29.7 | ||
| Morimoto et al[79] | Japan | TACE + RFA (19) | 3.6 ± 0.7 | 12/7/0 | 93.0 | NA |
| RFA (18) | 3.7 ± 0.6 | 16/2/0 | 80.0 | 28.0 | ||
| Kang et al[80] | China | TACE + RFA (19) | 6.7 ± 1.1 | 12/7/0 | 36.8 | NA |
| RFA (18) | 6.2 ± 1.2 | 12/6/0 | 16.7 | NA | ||
| Shen et al[81] | China | TACE + RFA (18) | 5.6 (2.2-15.8) | 4/14/0 | 73.3 | 50.0 |
| RFA (16) | 5.0 (2.3-12.3) | 6/10/0 | 20.4 | 18.7 | ||
| Zhang et al[82] | China | TACE + RFA (15) | 4.6 (2.3-7.1) | NA | NA | NA |
| RFA (15) | 4.1 (2.4-6.0) | NA | NA | NA |
- Citation: Facciorusso A, Serviddio G, Muscatiello N. Local ablative treatments for hepatocellular carcinoma: An updated review. World J Gastrointest Pharmacol Ther 2016; 7(4): 477-489
- URL: https://www.wjgnet.com/2150-5349/full/v7/i4/477.htm
- DOI: https://dx.doi.org/10.4292/wjgpt.v7.i4.477